Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome
ObjectiveDevelopment and validation of a clinical prediction model for receipt of pharmacotherapy for Neonatal Abstinence Syndrome (NAS).Study designData from three cohorts included in- utero opioid exposed neonates ≥37 weeks gestation. Primary outcome was the receipt of pharmacotherapy utilizing a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1527276/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242692431642624 |
|---|---|
| author | Shawana Bibi Shawana Bibi Rachana Singh Janis L. Breeze Jason Nelson Walter K. Kraft Jonathan M. Davis Jonathan M. Davis |
| author_facet | Shawana Bibi Shawana Bibi Rachana Singh Janis L. Breeze Jason Nelson Walter K. Kraft Jonathan M. Davis Jonathan M. Davis |
| author_sort | Shawana Bibi |
| collection | DOAJ |
| description | ObjectiveDevelopment and validation of a clinical prediction model for receipt of pharmacotherapy for Neonatal Abstinence Syndrome (NAS).Study designData from three cohorts included in- utero opioid exposed neonates ≥37 weeks gestation. Primary outcome was the receipt of pharmacotherapy utilizing a modified Finnegan Neonatal Abstinence Scoring System (FNASS). A stepwise multivariable logistic regression model was built and internally validated.ResultsOf 698 infants included, 430 received pharmacotherapy. The final model included seven predictors of receipt of pharmacotherapy: gestational age, exposure to maternal breast milk, type of maternal opioid medication, and exposure to heroin, cocaine, benzodiazepines, and/or antipsychotic medications. The model had an AUROC of 0.68 (95% CI: 0.64–0.72; optimism corrected 0.65).ConclusionOur prediction model was parsimonious and identified seven predictors associated with the need for PT. Larger cohort studies are needed to more definitively establish risk of significant NAS requiring pharmacotherapy. |
| format | Article |
| id | doaj-art-bdfcab80989343789b304342fa13b6d3 |
| institution | Kabale University |
| issn | 2296-2360 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj-art-bdfcab80989343789b304342fa13b6d32025-08-20T03:59:45ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-08-011310.3389/fped.2025.15272761527276Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndromeShawana Bibi0Shawana Bibi1Rachana Singh2Janis L. Breeze3Jason Nelson4Walter K. Kraft5Jonathan M. Davis6Jonathan M. Davis7Tufts Clinical and Translational Science Institute, Boston, MA, United StatesCleveland Clinic Children’s Hospital, Case Western Reserve University Lerner College of Medicine, Cleveland, OH, United StatesDepartment of Pediatrics, Tufts University School of Medicine, Boston, MA, United StatesTufts Clinical and Translational Science Institute, Boston, MA, United StatesTufts Clinical and Translational Science Institute, Boston, MA, United StatesDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United StatesTufts Clinical and Translational Science Institute, Boston, MA, United StatesDepartment of Pediatrics, Tufts University School of Medicine, Boston, MA, United StatesObjectiveDevelopment and validation of a clinical prediction model for receipt of pharmacotherapy for Neonatal Abstinence Syndrome (NAS).Study designData from three cohorts included in- utero opioid exposed neonates ≥37 weeks gestation. Primary outcome was the receipt of pharmacotherapy utilizing a modified Finnegan Neonatal Abstinence Scoring System (FNASS). A stepwise multivariable logistic regression model was built and internally validated.ResultsOf 698 infants included, 430 received pharmacotherapy. The final model included seven predictors of receipt of pharmacotherapy: gestational age, exposure to maternal breast milk, type of maternal opioid medication, and exposure to heroin, cocaine, benzodiazepines, and/or antipsychotic medications. The model had an AUROC of 0.68 (95% CI: 0.64–0.72; optimism corrected 0.65).ConclusionOur prediction model was parsimonious and identified seven predictors associated with the need for PT. Larger cohort studies are needed to more definitively establish risk of significant NAS requiring pharmacotherapy.https://www.frontiersin.org/articles/10.3389/fped.2025.1527276/fullneonatalabstinence syndromepredictorsclinicalpharmacotherapy |
| spellingShingle | Shawana Bibi Shawana Bibi Rachana Singh Janis L. Breeze Jason Nelson Walter K. Kraft Jonathan M. Davis Jonathan M. Davis Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome Frontiers in Pediatrics neonatal abstinence syndrome predictors clinical pharmacotherapy |
| title | Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| title_full | Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| title_fullStr | Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| title_full_unstemmed | Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| title_short | Clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| title_sort | clinical and demographic predictors of the need for pharmacotherapy in neonatal abstinence syndrome |
| topic | neonatal abstinence syndrome predictors clinical pharmacotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fped.2025.1527276/full |
| work_keys_str_mv | AT shawanabibi clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT shawanabibi clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT rachanasingh clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT janislbreeze clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT jasonnelson clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT walterkkraft clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT jonathanmdavis clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome AT jonathanmdavis clinicalanddemographicpredictorsoftheneedforpharmacotherapyinneonatalabstinencesyndrome |